abstract = "Preeclampsia is a hypertensive disorder that occurs
during pregnancy. It is a complex disease with unknown
pathogenesis and the leading cause of fetal and
maternal mortality during pregnancy. Using all drugs
currently under clinical trial for preeclampsia, we
extracted all their possible targets from the DrugBank
and ChEMBL databases and labeled them as targets. The
proteins labeled as off-targets were extracted in the
same way but while taking all antihypertensive drugs
which are inhibitors of ACE and/or angiotensin receptor
antagonist as query molecules. Classification models
were obtained for each of the 55 total proteins (45
targets and 10 off-targets) using the TPOT pipeline
optimization tool. The average accuracy of the models
in predicting the external dataset for targets and
off-targets was 0.830 and 0.850, respectively. The
combinations of models maximizing their virtual
screening performance were explored by combining the
desirability function and genetic algorithms. The
virtual screening performance metrics for the best
model were: the Boltzmann-Enhanced Discrimination of
ROC (BEDROC)alpha=160.9 = 0.258, the Enrichment Factor
(EF)1percent = 31.55 and the Area Under the
Accumulation Curve (AUAC) = 0.831. The most relevant
targets for preeclampsia were: AR, VDR, SLC6A2, NOS3
and CHRM4, while ABCG2, ERBB2, CES1 and REN led to the
most relevant off-targets. A virtual screening of the
DrugBank database identified estradiol, estriol,
vitamins E and D, lynestrenol, mifrepristone,
simvastatin, ambroxol, and some antibiotics and
antiparasitics as drugs with potential application in
the treatment of preeclampsia",
notes = "Grupo de Bio-Quimioinformatica, Universidad de Las
Americas, Quito 170513, Ecuador